JPH08508012A - ニューモシスチス症の治療のためのテルビナフィンの使用 - Google Patents
ニューモシスチス症の治療のためのテルビナフィンの使用Info
- Publication number
- JPH08508012A JPH08508012A JP6519792A JP51979294A JPH08508012A JP H08508012 A JPH08508012 A JP H08508012A JP 6519792 A JP6519792 A JP 6519792A JP 51979294 A JP51979294 A JP 51979294A JP H08508012 A JPH08508012 A JP H08508012A
- Authority
- JP
- Japan
- Prior art keywords
- terbinafine
- treatment
- day
- pneumonia
- primary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 title claims abstract description 21
- 229960002722 terbinafine Drugs 0.000 title claims abstract description 21
- 238000011282 treatment Methods 0.000 title claims abstract description 17
- 201000000317 pneumocystosis Diseases 0.000 claims abstract description 11
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 claims abstract description 6
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 claims abstract description 6
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 6
- 230000009863 secondary prevention Effects 0.000 claims abstract description 4
- 230000009862 primary prevention Effects 0.000 claims abstract description 3
- 229960004448 pentamidine Drugs 0.000 claims description 6
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 claims description 6
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 claims description 4
- 229940047766 co-trimoxazole Drugs 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- VKDGNNYJFSHYKD-UHFFFAOYSA-N 2,5-diamino-2-(difluoromethyl)pentanoic acid;hydron;chloride Chemical compound Cl.NCCCC(N)(C(F)F)C(O)=O VKDGNNYJFSHYKD-UHFFFAOYSA-N 0.000 claims description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 2
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 claims description 2
- 229960003362 carbutamide Drugs 0.000 claims description 2
- 229960002046 eflornithine hydrochloride Drugs 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims 2
- 238000009109 curative therapy Methods 0.000 claims 1
- RDYMFSUJUZBWLH-UHFFFAOYSA-N endosulfan Chemical compound C12COS(=O)OCC2C2(Cl)C(Cl)=C(Cl)C1(Cl)C2(Cl)Cl RDYMFSUJUZBWLH-UHFFFAOYSA-N 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 241000233870 Pneumocystis Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 201000005884 exanthem Diseases 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 206010017533 Fungal infection Diseases 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000024386 fungal infectious disease Diseases 0.000 description 3
- 229960005179 primaquine Drugs 0.000 description 3
- 206010043554 thrombocytopenia Diseases 0.000 description 3
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 2
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 229960003290 cortisone acetate Drugs 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 229960000860 dapsone Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003517 fume Substances 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- LUBUTTBEBGYNJN-UHFFFAOYSA-N 4-amino-n-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide;5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1.COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC LUBUTTBEBGYNJN-UHFFFAOYSA-N 0.000 description 1
- -1 6,6-dimethyl-2-heptene-4-ynyl Chemical group 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000025499 G6PD deficiency Diseases 0.000 description 1
- 206010018444 Glucose-6-phosphate dehydrogenase deficiency Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 231100000416 LDH assay Toxicity 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 240000001857 Phyllostachys elegans Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010054979 Secondary immunodeficiency Diseases 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003473 anti-pneumocystis Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 208000004526 exfoliative dermatitis Diseases 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 208000008605 glucosephosphate dehydrogenase deficiency Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 229960001624 pentamidine isethionate Drugs 0.000 description 1
- YBVNFKZSMZGRAD-UHFFFAOYSA-N pentamidine isethionate Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 YBVNFKZSMZGRAD-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- 229940101592 sulfamethoxazole 800 mg Drugs 0.000 description 1
- 201000009862 superficial mycosis Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 235000019669 taste disorders Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ニューモシスチス・カリニ肺炎の一次および二次予防および治療処置につ いての投薬法を作り出すためのテルビナフィンの使用。 2.ニューモシスチス・カリニ肺炎患者へのテルビナフィン3〜20mg/kg/日 の経口投与からなる、この型の肺炎の一次および二次予防および処置のためのテ ルビナフィンの使用。 3.トリメソプリムースルファメソキサゾール(コトリモキサゾール)、イセ チオン酸ペンタミジン、ダプソーン、トリメソプリムーダプソーン併用、トリメ ソトレキサート、エフロルニチンハイドロクロライド、クリンダミシンープリマ キン併用、イノシン類似体、ダプソーン誘導体またはカルブタミドとの併用によ る、ニューモシスチス・カリニ肺炎の一次および二次予防および治療処置のため の、経口投与3〜20mg/kg/日でのテルビナフィンの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT93A000154 | 1993-03-12 | ||
ITRM930154A IT1261776B (it) | 1993-03-12 | 1993-03-12 | Uso di terbinafina per il trattamento terapeutico della pneumocistosi. |
PCT/IT1994/000023 WO1994020082A1 (en) | 1993-03-12 | 1994-03-11 | Use of terbinafine for the therapeutic treatment of pneumocystosis |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH08508012A true JPH08508012A (ja) | 1996-08-27 |
Family
ID=11401596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6519792A Ceased JPH08508012A (ja) | 1993-03-12 | 1994-03-11 | ニューモシスチス症の治療のためのテルビナフィンの使用 |
Country Status (12)
Country | Link |
---|---|
US (1) | US5719192A (ja) |
EP (1) | EP0692963B1 (ja) |
JP (1) | JPH08508012A (ja) |
KR (1) | KR100343031B1 (ja) |
AT (1) | ATE219667T1 (ja) |
CA (1) | CA2157590C (ja) |
DE (1) | DE69430867T2 (ja) |
DK (1) | DK0692963T3 (ja) |
ES (1) | ES2178650T3 (ja) |
IT (1) | IT1261776B (ja) |
PT (1) | PT692963E (ja) |
WO (1) | WO1994020082A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0003360D0 (en) | 2000-02-14 | 2000-04-05 | Novartis Ag | Monoclonal antibodies |
GB0014448D0 (en) * | 2000-06-13 | 2000-08-09 | Novartis Ag | Organic compounds |
US7244703B2 (en) * | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
US7112561B2 (en) | 2003-12-08 | 2006-09-26 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for insulin treatment |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9111611D0 (en) * | 1991-05-30 | 1991-07-24 | Sandoz Ltd | Liposomes |
-
1993
- 1993-03-12 IT ITRM930154A patent/IT1261776B/it active IP Right Grant
-
1994
- 1994-03-11 AT AT94910517T patent/ATE219667T1/de not_active IP Right Cessation
- 1994-03-11 PT PT94910517T patent/PT692963E/pt unknown
- 1994-03-11 CA CA002157590A patent/CA2157590C/en not_active Expired - Fee Related
- 1994-03-11 KR KR1019950703775A patent/KR100343031B1/ko not_active IP Right Cessation
- 1994-03-11 DE DE69430867T patent/DE69430867T2/de not_active Expired - Fee Related
- 1994-03-11 EP EP94910517A patent/EP0692963B1/en not_active Expired - Lifetime
- 1994-03-11 JP JP6519792A patent/JPH08508012A/ja not_active Ceased
- 1994-03-11 US US08/525,526 patent/US5719192A/en not_active Expired - Lifetime
- 1994-03-11 DK DK94910517T patent/DK0692963T3/da active
- 1994-03-11 WO PCT/IT1994/000023 patent/WO1994020082A1/en active IP Right Grant
- 1994-03-11 ES ES94910517T patent/ES2178650T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DK0692963T3 (da) | 2002-10-14 |
ATE219667T1 (de) | 2002-07-15 |
ITRM930154A1 (it) | 1994-09-12 |
CA2157590A1 (en) | 1994-09-15 |
CA2157590C (en) | 2006-01-10 |
EP0692963A1 (en) | 1996-01-24 |
PT692963E (pt) | 2002-10-31 |
DE69430867D1 (de) | 2002-08-01 |
DE69430867T2 (de) | 2003-01-02 |
WO1994020082A1 (en) | 1994-09-15 |
IT1261776B (it) | 1996-06-03 |
EP0692963B1 (en) | 2002-06-26 |
US5719192A (en) | 1998-02-17 |
KR100343031B1 (ko) | 2002-11-07 |
ES2178650T3 (es) | 2003-01-01 |
ITRM930154A0 (it) | 1993-03-12 |
KR960700699A (ko) | 1996-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wasser et al. | Chronic renal failure after ingestion of over-the-counter chromium picolinate | |
EP1443933B1 (en) | Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents | |
Schwartz et al. | The chemotherapy of pulmonary tuberculosis with pyrazinamide used alone and in combination with streptomycin, para-aminosalicylic acid, or isoniazid | |
Cummings et al. | The influence of cortisone and streptomycin on experimental tuberculosis in the albino rat | |
EP0344880A2 (en) | Pharmaceutical compositions with anti-cancer activity | |
JPS63500869A (ja) | 多発硬化症治療剤 | |
Wold et al. | Allergic (Löffler’s) Pneumonitis Occuring During Antituberculous Chemotherapy: Report of Three Cases | |
US5104875A (en) | Combination preparations containing rifampicin and thioacetazon | |
JPH08508012A (ja) | ニューモシスチス症の治療のためのテルビナフィンの使用 | |
US20220016118A1 (en) | Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof | |
JPH05504774A (ja) | エイズ治療を増進するためのメタロポルフィリン類の使用 | |
Osterman | A COMPARISON BETWEEN PLACEBO, PIZOTIFEN AND 1‐ISOPROPYL‐3‐HYDROXY‐5‐SEMICARBAZONO‐6‐OXO‐2.3. 5.6.‐TETRAHYDROINDOL (DIVASCAN®) IN MIGRAINE PROPHYLAXIS | |
Kong et al. | Cryptococcosis in a renal unit | |
US6262031B1 (en) | Method for treating pediculosis capitisinfestation | |
Singapore Tuberculosis Service/British Medical Research Council | Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis | |
EP1631291B1 (en) | Use of tyrosine kinase inhibitors to treat diabetes | |
DeConti | Procarbazine in the management of late Hodgkin's disease | |
Nissani et al. | Stuttering caused by gabapentin | |
Cecchin et al. | Treatment of cyclosporine-induced gingival hypertrophy | |
Dorr et al. | Interaction between cisplatin and mesna in mice | |
Maxim Steinbach et al. | Vitamin C in experimental tuberculosis | |
JPH01313433A (ja) | 抗hiv剤 | |
Taillan et al. | MACOP-B chemotherapy for the treatment of high-grade lymphomas in patients with HIV-1 infection | |
Scher et al. | Phase-II trial of 1, 2-diaminocyclohexane (4-carboxyphthalato) platinum (II)(DACCP) in non-small cell lung cancer | |
US3320132A (en) | Composition containing 1-beta-d-arabinofuranosylcytosine useful in treating mice tumors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040518 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040813 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20050628 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20061010 |
|
A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20070227 |